Expert Insights: Key Ketamine Patient Considerations

ASCP 2026 Spotlight: Refining Ketamine Patient Care

At the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Dr. Benjamin Brody delivered critical insights on patient considerations that are reshaping how clinicians approach ketamine therapy. His presentation, titled "Key Issues in Ketamine," addressed fundamental questions that directly impact how patients receive and respond to ketamine treatment across all delivery methods.

This timing is particularly significant as ketamine therapy continues its rapid expansion in 2026, with sublingual troches representing one of the fastest-growing segments of at-home ketamine treatment. Dr. Brody's expert perspective comes at a crucial moment when standardization of patient selection criteria and safety protocols remains inconsistent across different providers and delivery formats.

The ASCP platform gives these insights considerable weight in the psychiatric community, as the organization represents leading voices in clinical psychopharmacology. When presented at this venue, patient consideration guidelines often influence treatment protocols across various ketamine delivery methods, including the increasingly popular troche format.

What This Means for Troche Treatment Protocols

While Dr. Brody's presentation addressed ketamine therapy broadly, the patient considerations he highlighted have specific implications for sublingual troche treatment. Unlike IV infusions administered in clinical settings, troches require patients to manage their own dosing environment, timing, and safety monitoring at home.

The expert focus on patient considerations likely addresses several critical areas that directly impact troche therapy success. Patient selection criteria become even more stringent for at-home treatment, as providers must identify candidates who can safely self-administer while maintaining proper set and setting protocols. This includes evaluating patients' home environments, support systems, and ability to follow precise dosing instructions.

Troche-specific patient considerations also involve the unique pharmacokinetics of sublingual absorption. Unlike the predictable bioavailability of IV ketamine, troches require patients to understand proper dissolution techniques, timing of swallowing, and factors that affect absorption rates. Dr. Brody's insights likely reinforce the importance of comprehensive patient education before initiating troche therapy.

The presentation timing suggests that as more patients transition from in-office infusions to at-home troches, the psychiatric community is recognizing the need for more refined patient assessment protocols. This evolution reflects the growing understanding that successful troche therapy requires different patient characteristics and preparation compared to clinic-based treatments.

Impact on Compounding and Dosing Standards

Expert recommendations from venues like ASCP often translate into updated guidelines for compounding pharmacies that prepare ketamine troches. If Dr. Brody's presentation emphasized specific patient factors that influence treatment response, these insights could lead to more personalized troche formulations and dosing strategies.

For patients currently using troches, this type of expert input typically results in enhanced monitoring protocols and more sophisticated titration schedules. Providers may implement additional patient screening measures, particularly around cardiovascular health, psychiatric stability, and medication interactions that could affect troche safety or efficacy.

The focus on patient considerations also suggests potential updates to the informed consent process for troche therapy. As the field matures, patients can expect more detailed discussions about individual risk factors, realistic outcome expectations, and specific safety measures required for successful at-home treatment.

Looking Ahead: Practical Implications

For patients considering or currently using ketamine troches, expert presentations like Dr. Brody's typically signal upcoming changes in treatment protocols. This could mean more comprehensive pre-treatment evaluations, enhanced patient education requirements, or updated safety monitoring procedures for at-home dosing.

Providers specializing in troche therapy will likely incorporate these expert recommendations into their practice protocols, potentially affecting everything from initial patient consultations to ongoing treatment adjustments. Patients should expect their providers to ask more detailed questions about their medical history, home environment, and previous responses to psychiatric medications.

The emphasis on patient considerations also reinforces the importance of choosing experienced providers who stay current with evolving best practices. As the field continues to mature, the gap between expert-guided care and less sophisticated treatment approaches will likely become more pronounced, making provider selection increasingly critical for optimal outcomes.

This expert focus on patient-centered care represents a positive development for the ketamine therapy field, suggesting continued refinement of treatment protocols that prioritize both safety and efficacy in real-world clinical practice.